NUWELLIS INC

Nuwellis Inc. specializes in the design, development, and manufacturing of advanced medical devices, particularly in the realm of cardiovascular and renal therapeutic systems. Leveraging expertise in biomedical engineering and precision manufacturing, the company focuses on creating minimally invasive technologies that address acute and chronic clinical conditions. Their technical capabilities include implantable device integration, fluid dynamics modeling, biocompatible material selection, and regulatory-compliant production processes aligned with ISO 13485 standards. Nuwellis differentiates itself through its focus on novel catheter-based systems and proprietary mechanisms for hemodynamic support, demonstrating deep domain knowledge in interventional cardiology and critical care applications. Award history is not available to confirm specific agency engagements, so no definitive patterns of federal contract work can be inferred. The company’s primary NAICS code, 339113, corresponds to Surgical and Medical Instrument Manufacturing, indicating a core focus on producing Class II and Class III medical devices under FDA oversight. This positions Nuwellis within the broader life sciences and healthcare technology sector, serving hospitals, clinical research institutions, and healthcare providers through FDA-cleared and approved therapeutic solutions. Nuwellis Inc. is structured as a small business (2L entity) headquartered in Eden Prairie, Minnesota, with no publicly disclosed government certifications such as 8(a), HUBZone, or WOSB. The company operates primarily as a private-sector medical technology developer, with its market presence centered on innovation in interventional cardiology and renal therapy. Its geographic footprint is concentrated in the Upper Midwest, supporting regional healthcare ecosystems while engaging in national distribution channels for its medical devices.